Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
Étude IPH4102-101 : étude de phase 1, en escalade de dose, de première administration à l’homme, évaluant la tolérance du IPH4102, un anticorps humanisé anti-KIR3DL2, chez des patients ayant un lymphome cutané à cellules T (LCCT) en rechute ou réfractaire. [essai clos aux inclusions] https://kusajili.fr:443/Trial/yCMGyzGRD06z6mXXgwZumA%24etude-iph4102-101-etude-de-phase-1-en-escalade-de-dose-de-premiere-administration-a-lhomme-evaluant-la-tolerance-du-iph4102-un-
I have read and accept the terms of use of the site and the Privacy Policy
Send your message